Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
J Am Acad Dermatol ; 90(4): 759-766, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38070541

RESUMEN

BACKGROUND: Psoralen + ultraviolet-A (PUVA) is associated with photocarcinogenesis. However, carcinogenic risk with other ultraviolet phototherapies remains unclear. OBJECTIVE: Evaluate whether phototherapy without psoralens increases skin cancer risk. METHODS: Retrospective cohort study of patients treated at a teaching-hospital phototherapy center (1977-2018). Skin cancer records were validated against pathology reports. Age-standardized incidence rates (ASIRs) of skin cancer were evaluated for gender, skin phototype, diagnosis, ultraviolet modality, anatomical site; and compared to provincial population incidence rates (2003). RESULTS: In total, 3506 patients treated with broadband-ultraviolet-B, narrowband-UVB and/or combined UVAB were assessed with a mean follow-up of 7.3 years. Majority of patients had psoriasis (60.9%) or eczema (26.4%). Median number of treatments was 43 (1-3598). Overall, 170 skin cancers (17 melanoma, 33 squamous cell carcinoma and 120 basal cell carcinoma) occurred in 79 patients. Patient-based and tumor-based ASIR of skin cancer was 149 (95% CI: 112-187)/100,000 and 264 (219-309)/100,000 person-years, respectively. There was no significant difference between tumor-based ASIRs for melanoma, squamous cell carcinoma, and basal cell carcinoma compared to the general population; or in phototherapy patients with-psoriasis or eczema; or immunosuppressants. No cumulative dose-response correlation between UVB and skin cancer was seen. LIMITATIONS: Treatment and follow-up duration. CONCLUSION: No increased risk of melanoma and keratinocyte cancer was found with phototherapy.


Asunto(s)
Carcinoma Basocelular , Carcinoma de Células Escamosas , Eccema , Furocumarinas , Melanoma , Psoriasis , Neoplasias Cutáneas , Terapia Ultravioleta , Humanos , Incidencia , Melanoma/etiología , Melanoma/complicaciones , Estudios Retrospectivos , Terapia Ultravioleta/efectos adversos , Neoplasias Cutáneas/epidemiología , Neoplasias Cutáneas/etiología , Fototerapia/efectos adversos , Psoriasis/complicaciones , Carcinoma Basocelular/etiología , Carcinoma Basocelular/complicaciones , Carcinoma de Células Escamosas/etiología , Carcinoma de Células Escamosas/complicaciones , Eccema/complicaciones
2.
World J Surg Oncol ; 11(1): 193, 2013 Aug 13.
Artículo en Inglés | MEDLINE | ID: mdl-23941693

RESUMEN

BACKGROUND: Although conventional adenocarcinoma accounts for the majority of prostatic carcinomas, it is important to recognize rare variants, like basal cell carcinoma (BCC), which has distinctive histopathological and biological features. CASE REPORT: We analyzed three cases of prostatic BCC and all of them complained of acute urinary retention and digital rectal examination disclosed a stony hard prostate. However, all of them presented with low prostate-specific antigen. The diagnosis relied on transrectal ultrasound-guided needle biopsies or transurethral resection of the prostate (TURP). The microscopic findings suggested basaloid cells with large pleomorphic nuclei and scant cytoplasm, showing peripheral palisading and forming solid nests, and immunohistochemical markers like 34ßE12, p63 and Ki67 staining, were positive. After active treatment, two of the patients are alive with tumor and one died five months after discharge from our hospital.


Asunto(s)
Neoplasias Óseas/secundario , Carcinoma Basocelular/patología , Neoplasias Hepáticas/secundario , Neoplasias Pulmonares/secundario , Neoplasias de la Próstata/patología , Anciano , Biomarcadores de Tumor/análisis , Neoplasias Óseas/complicaciones , Neoplasias Óseas/terapia , Carcinoma Basocelular/complicaciones , Carcinoma Basocelular/terapia , Terapia Combinada , Humanos , Técnicas para Inmunoenzimas , Neoplasias Hepáticas/complicaciones , Neoplasias Hepáticas/terapia , Neoplasias Pulmonares/complicaciones , Neoplasias Pulmonares/terapia , Masculino , Persona de Mediana Edad , Pronóstico , Neoplasias de la Próstata/complicaciones , Neoplasias de la Próstata/terapia , Estudios Retrospectivos , Literatura de Revisión como Asunto , Resección Transuretral de la Próstata
3.
G Ital Dermatol Venereol ; 146(4): 301-5, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21785397

RESUMEN

Dermatological radiotherapy has used for decades in the treatment of skin diseases with very good results. The Florentine school has always played a fundamental role in the development of this technique, this is where a phototherapy institute, which was going, in the future, to be 1st one in Italy to perform contact radiotherapy regularly, started. As time went by and with the development to new therapeutical modalities, the roentgentherapy met with a decreasing consent. So far, it is still proposed as an effective therapeutically modality in dermatological oncology, if even in selected cases. Basal cell carcinomas can reach big dimensions mainly for recurrence or because the tumor was overlooked for a long time. We bring to attention the case of a 65-year-old man presenting an ulcerated, sharp-bordered, infiltrating and bleeding lesion, occupying most of the left wing of the nose, with a diameter of about 3 cm. The man hadn't received any previous treatment. The lesion was subjected to a biopsy and the istopathological analysis diagnosed an ulcus rodens. The man refused the complete surgical removal, and was thus treated with roentgentherapy, with satisfying results and without any complications in the irradiated area. The patient didn't show any relapse after one year of follow-up. Radiotherapy can still be considered as an effective therapeutical alternative both for lesion requiring a surgical approach and for those developing in patients that couldn't be subjected to any other therapies.


Asunto(s)
Carcinoma Basocelular/radioterapia , Neoplasias Nasales/radioterapia , Enfermedades de la Piel/radioterapia , Anciano , Biopsia , Carcinoma Basocelular/complicaciones , Carcinoma Basocelular/patología , Fraccionamiento de la Dosis de Radiación , Estética , Humanos , Masculino , Neoplasias Nasales/complicaciones , Neoplasias Nasales/patología , Úlcera Cutánea/etiología , Úlcera Cutánea/radioterapia , Resultado del Tratamiento
6.
J Dermatol ; 19(11): 715-8, 1992 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-1293159

RESUMEN

Xeroderma pigmentosum is a rare recessive disease with sun sensitivity, increased freckling and defective DNA repair. Xeroderma pigmentosum patients have more than a 1000-fold increased risk of developing skin cancer including basal cell carcinoma, squamous cell carcinoma and melanoma. We studied chemoprevention of new skin cancers with oral retinoids in xeroderma pigmentosum patients who had multiple skin cancers. Xeroderma pigmentosum patients were cleared of all pre-existing tumors surgically and then treated with high dose (2 mg/kg/day) oral isotretinoin (13-cis retinoic acid, Accutane) for two years and then for one year off treatment. Patients were examined at regular intervals for new tumor formation and for side effects. Five xeroderma pigmentosum patients had a total of 121 basal or squamous cell carcinomas in 2 years before treatment and only 25 tumors during 2 years of treatment. The tumor frequency increased 8.5-fold after the drug was discontinued (New Engl J Med 318: 1633-1637, 1988). Toxicity (cutaneous, triglyceride, liver-function or skeletal abnormalities) prompted subsequent use of a low dose protocol. Patients were treated initially with 0.5 mg/kg/day oral isotretinoin and the dose was increased sequentially to 1.0 or 1.5 mg/kg/day. We found that toxicity was less with the lower doses. The lowest effective, least toxic dose varied among the xeroderma pigmentosum patients.


Asunto(s)
Isotretinoína/administración & dosificación , Neoplasias Cutáneas/prevención & control , Xerodermia Pigmentosa/complicaciones , Administración Oral , Adolescente , Adulto , Carcinoma Basocelular/complicaciones , Carcinoma Basocelular/prevención & control , Carcinoma de Células Escamosas/complicaciones , Carcinoma de Células Escamosas/prevención & control , Niño , Femenino , Humanos , Isotretinoína/efectos adversos , Masculino , Persona de Mediana Edad , Neoplasias Cutáneas/complicaciones , Xerodermia Pigmentosa/patología
7.
Geriatrics ; 41(8): 71-4, 77-80, 1986 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-3732810

RESUMEN

Topical steroid creams and ointments, applied once or twice daily, can help control psoriatic lesions and reduce itching. Intermediate-strength compounds are preferable for use in the elderly. Skin biopsy interpreted as psoriasiform dermatitis or nonspecific dermatitis, rather than psoriasis, should be considered a possible result of malignancy.


Asunto(s)
Psoriasis/tratamiento farmacológico , Esteroides/uso terapéutico , Administración Tópica , Anciano , Carcinoma Basocelular/complicaciones , Humanos , Persona de Mediana Edad , Terapia PUVA , Psoriasis/etiología , Psoriasis/microbiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA